The Managing Director of World Investments, Mr. Zayed bin Aweidha, hosted members of the Canadian strategic team from Resverlogix for biological services, led by the company’s CEO, Mr. Donald J. McCaffrey, at the World Investments headquarters in Dubai, United Arab Emirates.
The high-level meeting focused on the potential for a joint project between the two parties, including the establishment of an international fund worth millions of dollars for Resverlogix’s biotechnological product, APABETALONE, which has shown cardiovascular protective benefits in patients with high-risk heart, vascular, diabetes, and kidney diseases, using advanced epigenetics to transform and switch multiple disease-associated genes on or off.
APABETALONE is also known to possess a dual approach of antiviral and anti-inflammatory gene suppression, which holds very high potential as a significant treatment for COVID-19.
